Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis

(2019) Peter C. Taylor et al.   Arthritis & Rheumatology

Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

(2019) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

(2018) Ronald F van Vollenhoven et al.   LANCET

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

(2018) Kim Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   RHEUMATOLOGY

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis

(2017) Christopher Banfield et al.   JOURNAL OF CLINICAL PHARMACOLOGY

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions

(2016) Bo Feng et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity

(2016) C. A. Dendrou et al.   Science Translational Medicine

Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3

(2015) Wendy P. Battisti et al.   ANNALS OF INTERNAL MEDICINE

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

(2015) Philip J. Mease   CURRENT OPINION IN RHEUMATOLOGY

Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis

(2014) Patompong Ungprasert et al.   CLINICAL RHEUMATOLOGY

Inhibition of JAK-STAT signaling stimulates adult satellite cell function

(2014) Feodor D Price et al.   NATURE MEDICINE

STAT3 signaling controls satellite cell expansion and skeletal muscle repair

(2014) Matthew Timothy Tierney et al.   NATURE MEDICINE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study

(2013) Wei-Sheng Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

Tyk2 is a therapeutic target for psoriasis-like skin inflammation

(2013) M. Ishizaki et al.   INTERNATIONAL IMMUNOLOGY

TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses In Vivo

(2012) Michaela Prchal-Murphy et al.   PLoS One

Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo

(2011) M. Ishizaki et al.   JOURNAL OF IMMUNOLOGY

Risk of venous thromboembolism with rheumatoid arthritis

(2008) Fadi Matta et al.   THROMBOSIS AND HAEMOSTASIS